|
How we treat higher-risk myelodysplastic syndromes
|
Dec 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
Jul 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
|
Jun 2015
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes
|
Sep 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
|
Oct 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
|
Aug 2013
|
Blood
|
aplastic anemia
|
|
How we treat lower risk myelodysplastic syndromes.
|
Apr 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
The myelodysplastic syndrome as a prototypical epigenetic disease.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
|
Jul 2020
|
Blood
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
How I treat acquired aplastic anemia
|
Jan 2017
|
Blood
|
aplastic anemia
|
